Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12766316 | 1.00 | TGFBR1 (0.34) | TGFBR1TDP1MMETSHR | |
| SCHEMBL19483467 | 0.82 | — | — | |
| SCHEMBL2625030 | 0.81 | ALDH1A1 (0.35) | TDP1TSHR | |
| SCHEMBL10166040 | 0.81 | ALDH1A1 (0.35) | TDP1TSHR | |
| SCHEMBL23306943 | 0.80 | MMP1 (0.35) | TGFBR1TSHR | |
| SCHEMBL21153561 | 0.80 | MME (0.43) | MME | |
| SCHEMBL18932853 | 0.79 | ALDH1A1 (0.32) | TDP1TSHR | |
| SCHEMBL7602603 | 0.79 | ALDH1A1 (0.44) | — | |
| SCHEMBL24494714 | 0.79 | ACE (0.39) | TDP1 | |
| SCHEMBL19361692 | 0.79 | TDP1 (0.30) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023217744-A1 | PRODRUGS OF GLP-1 POLYPEPTIDE AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-11-16 | — | — | WO | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023028338-A2 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-11572398-B2 | GLP-1 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2023-02-07 | — | — | US | disclosed |
| WO-2022235699-A2 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-11358985-B2 | Tripeptide compound, preparation method therefor, and application thereof | NORTHWEST UNIVERSITY (CN) | 2022-06-14 | — | — | US | disclosed |
| WO-2022096636-A1 | GLP-1 PRODRUGS AND USES HEREOF | NOVO NORDISK A/S (DK) | 2022-05-12 | — | — | WO | disclosed |
| US-20170320927-A1 | GLP-1 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-11-09 | — | — | US | disclosed |
| US-20170320927-A1 | GLP-1 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-11-09 | — | — | US | disclosed |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-21 | — | — | US | disclosed |
| US-9725483-B2 | Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions | LIPOTEC, S.A. (ES) | 2017-08-08 | — | — | US | disclosed |
| US-20170144998-A1 | ELASTASE INHIBITORS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2017-05-25 | — | — | US | disclosed |
| US-9656972-B2 | Compounds for treatment of cystic fibrosis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-06-09 | — | — | US | disclosed |
| US-8653278-B2 | Isoform selective HDAC inhibitors | GEORGETOWN UNIVERSITY (US) | 2014-02-18 | — | — | US | disclosed |
| US-20100196502-A1 | Isoform Selective HDAC Inhibitors | GEORGETOWN UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | TGFBR1 701/4885TDP1 3930/4885MME 158/4885 |
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, ELANE, OTC | TGFBR1 2445/4885TDP1 4703/4885MME 396/4885 |
| US-11358985-B2 | Tripeptide compound, preparation method therefor, and application thereof | VIP, PREP, ACE | TGFBR1 997/4885TDP1 2218/4885MME 85/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | TGFBR1 366/4885TDP1 4559/4885MME 1308/4885 |
| US-11572398-B2 | GLP-1 derivatives and uses thereof | GLP1R, GIPR, GCG | TGFBR1 2005/4885TDP1 3599/4885MME 1401/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | TGFBR1 506/4885TDP1 3682/4885MME 104/4885 |
| US-20100196502-A1 | Isoform Selective HDAC Inhibitors | HDAC5, HDAC6, HDAC3 | TGFBR1 2340/4885TDP1 1198/4885MME 3166/4885 |
| US-20170320927-A1 | GLP-1 Derivatives and Uses Thereof | GLP1R, GIPR, GCG | TGFBR1 2005/4885TDP1 3599/4885MME 1401/4885 |
| US-20170144998-A1 | ELASTASE INHIBITORS | SERPINB1, ELANE, CELA1 | TGFBR1 3602/4885TDP1 1042/4885MME 53/4885 |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | VIP, PREP, ACE | TGFBR1 997/4885TDP1 2218/4885MME 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.